Journals / The Anatolian Journal of Cardiology / 2020 / Cilt: 24 - Sayı: 3

Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey)

Pages
192–200
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

MetS and its components have a similar discriminative ability for CV events.(Anatol J Cardiol 2020; 24: 192-200)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Metabolic syndrome (MetS) includes several cardiovascular (CV) risk factors.
📊
Key Findings & Data:This study aimed to assess CV risk of MetS, contribu-tion of its components to the risk, and whether MetS provides additional risk beyond its components.Methods: The Prospective Urban Rural Epidemiology (PURE) Turkey cohort included 3933 individuals aged between 35 and 70 years, with a median follow-up of 8.9 years.
💡
Conclusion & Impact:MetS and its components have a similar discriminative ability for CV events.(Anatol J Cardiol 2020; 24: 192-200)
🔬Design:Modeling & Simulation
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: Metabolic syndrome (MetS) includes several cardiovascular (CV) risk factors. This study aimed to assess CV risk of MetS, contribu-tion of its components to the risk, and whether MetS provides additional risk beyond its components.Methods: The Prospective Urban Rural Epidemiology (PURE) Turkey cohort included 3933 individuals aged between 35 and 70 years, with a median follow-up of 8.9 years. MetS was diagnosed as the presence of any of the following criteria: high blood pressure, high fasting plasma glucose, abdominal obesity, low HDL-cholesterol, or high triglycerides. The primary outcome was the composite of fatal CV events, non-fatal myocardial infarction, stroke or heart failure, adjusted for age, sex, smoking, family history of CV diseases, and LDL-cholesterol.Results: The primary outcome was more common in the MetS group [178 (9.2%) vs. 70 (3.5%); corresponding incidence rate of 11.3 vs. 4.2 per 1000 person-years; log-rank p<0.001]. Each component was significantly associated with the primary outcome; however, when the components were sequentially included in the model, abdominal obesity and high triglycerides did not provide additional risk on top of the other three com-ponents. The hazard ratio for MetS for the primary outcome was 2.12 (95% confidence interval 1.59–2.81, p<0.001), and the discriminative ability (c-statistics) of the models with MetS and the components was similar.Conclusion: MetS increases the risk of CV events more than two-fold. High blood pressure, high fasting plasma glucose, and low HDL-cholester-ol are the top three components of MetS for CV risk. MetS and its components have a similar discriminative ability for CV events.(Anatol J Cardiol 2020; 24: 192-200)

🔖

Cite This Article

OĞUZ, A., KESKİNER, M. V., KILIÇKAPI, M., GÜLEÇ, H. S., ALTUNTAŞ, Y., KARŞIDAĞ, K., TEMİZHAN, A., ÇALIK, B. T., RANGARAJAN, S., YUSUF, S. (2020). Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey). The Anatolian Journal of Cardiology, Cilt: 24 - Sayı: 3, 192–200. https://ajindex.com/articles/366662

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Grundy SM. Metabolic syndrome: connecting and reconciling car-diovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-100
  2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and clas-sification of diabetes mellitus provisional report of a WHO consul-tation. Diabet Med 1998; 15: 539-53
  3. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237-52
  4. Expert Panel on Detection E, Treatment of High Blood Cholester-ol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
  5. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consen-sus Group. The metabolic syndrome--a new worldwide definition. Lancet 2005; 366: 1059-62
  6. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Do-nato KA, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federa-tion Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and In-ternational Association for the Study of Obesity. Circulation 2009; 120: 1640-5
  7. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes As-sociation; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European As-sociation for the Study of Diabetes. Diabetes Care 2005; 28: 2289-304
  8. Abacı A, Kılıçkap M, Göksülük H, Karaaslan D, Barçın C, Kayıkçıoğlu M, et al. Data on prevalence of metabolic syndrome in Turkey: Sys-tematic review, meta-analysis and meta-regression of epidemio-logical studies on cardiovascular risk factors. Turk Kardiyol Dern Ars 2018; 46: 591-601
  9. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low choles